NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday
TVTX Stock | USD 18.75 0.02 0.11% |
Slightly above 67% of Travere Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that many traders are alarmed. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
Travere |
U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday.
Read at benzinga.com
Travere Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Travere Therapeutics Fundamental Analysis
We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Travere Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Travere Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.
Peers
Travere Therapeutics Related Equities
PTGX | Protagonist Therapeutics | 2.72 | ||||
RVMD | Revolution Medicines | 0.53 | ||||
IDYA | Ideaya Biosciences | 0.14 | ||||
CYTK | Cytokinetics | 0.1 | ||||
GPCR | Structure Therapeutics | 0.06 | ||||
NUVL | Nuvalent | 1.01 | ||||
APLS | Apellis Pharmaceuticals | 1.09 | ||||
KROS | Keros Therapeutics | 1.24 | ||||
AKRO | Akero Therapeutics | 1.54 | ||||
PCVX | Vaxcyte | 1.77 | ||||
RNA | Avidity Biosciences | 2.04 | ||||
MGTX | MeiraGTx Holdings | 3.40 | ||||
STOK | Stoke Therapeutics | 3.63 | ||||
COGT | Cogent Biosciences | 6.95 | ||||
VTYX | Ventyx Biosciences | 7.64 | ||||
LEGN | Legend Biotech | 8.96 | ||||
ANAB | AnaptysBio | 34.95 |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.